• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过直肠指检进行常规前列腺癌筛查后的疾病特异性生存率。

Disease-specific survival following routine prostate cancer screening by digital rectal examination.

作者信息

Gerber G S, Thompson I M, Thisted R, Chodak G W

机构信息

Department of Surgery, University of Chicago Hospitals and Clinics, IL.

出版信息

JAMA. 1993 Jan 6;269(1):61-4.

PMID:8416407
Abstract

OBJECTIVE

To assess prostate cancer mortality in men undergoing routine screening by routine digital rectal examination.

DESIGN

Cohort study with a median follow-up period of 75 months.

SETTING

Population consisted of volunteers at a university clinic and men in an institutional health maintenance clinic.

PATIENTS

Fifty-six men with a mean age of 65 years (range, 52 to 79 years) diagnosed with prostate cancer.

INTERVENTIONS

Patients treated initially by observation, external or interstitial radiotherapy, radical prostatectomy, hormone therapy, or combination.

MAIN OUTCOME MEASURES

Kaplan-Meier analysis of time to local progression, distant metastases, death from all causes, and death from prostate cancer. Mantel-Haenszel log-rank statistic was used to compare outcome in men diagnosed on initial examination with those diagnosed on subsequent examinations.

RESULTS

Clinically localized prostate cancer was diagnosed in 73% during an initial examination and 83% on subsequent examinations and (P.35). Grade distribution of tumors was similar in both groups. Overall 5 and 10 year survival of all cancer patients was 85% and 67%, respectively. Death from prostate cancer was 8% (3/38) in men diagnosed on initial examination and 33% (6/18) during subsequent examinations. Five- and 10-year disease-specific survival was 97% and 86%, respectively, for men diagnosed during the first rectal examination compared with only 81% and 57%, respectively, for men diagnosed on subsequent rectal examinations (P = .02).

CONCLUSION

Routine screening for prostate cancer by annual digital rectal examination alone may be insufficiently frequent and/or sensitive to prevent significant mortality from this disease [corrected].

摘要

目的

评估通过常规直肠指检进行常规筛查的男性前列腺癌死亡率。

设计

队列研究,中位随访期为75个月。

地点

研究人群包括大学诊所的志愿者和机构健康维护诊所的男性。

患者

56名平均年龄65岁(范围52至79岁)的前列腺癌确诊患者。

干预措施

患者最初接受观察、外照射或组织间放疗、根治性前列腺切除术、激素治疗或联合治疗。

主要观察指标

采用Kaplan-Meier法分析局部进展时间、远处转移、全因死亡和前列腺癌死亡情况。使用Mantel-Haenszel对数秩统计量比较初次检查确诊的男性与后续检查确诊的男性的结局。

结果

初次检查时73%的患者被诊断为临床局限性前列腺癌,后续检查时这一比例为83%(P = 0.35)。两组肿瘤分级分布相似。所有癌症患者的5年和10年总生存率分别为85%和67%。初次检查确诊的男性中前列腺癌死亡率为8%(3/38),后续检查确诊的男性中这一比例为33%(6/18)。首次直肠检查确诊的男性5年和10年疾病特异性生存率分别为97%和86%,而后续直肠检查确诊的男性分别仅为81%和57%(P = 0.02)。

结论

仅通过每年一次的直肠指检进行前列腺癌常规筛查,其频率和/或敏感性可能不足以预防该疾病导致的显著死亡率[已修正]。

相似文献

1
Disease-specific survival following routine prostate cancer screening by digital rectal examination.通过直肠指检进行常规前列腺癌筛查后的疾病特异性生存率。
JAMA. 1993 Jan 6;269(1):61-4.
2
Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.对于根治性前列腺切除术后前列腺特异性抗原检测不到的男性患者,在常规随访中不再需要进行直肠指检:随访的意义
Eur Urol. 2005 Dec;48(6):906-10. doi: 10.1016/j.eururo.2005.07.006. Epub 2005 Aug 2.
3
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.在筛查间隔期发现的前列腺癌男性的疾病特异性生存:随访 11 年后欧洲前列腺癌筛查随机研究-鹿特丹的结果。
Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.
4
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.病理分期晚期前列腺癌的辅助放疗:一项随机临床试验。
JAMA. 2006 Nov 15;296(19):2329-35. doi: 10.1001/jama.296.19.2329.
5
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.前列腺癌根治术后生化复发后,前列腺特异抗原(PSA)倍增时间作为临床进展的预测指标。
Mayo Clin Proc. 2001 Jun;76(6):576-81. doi: 10.4065/76.6.576.
6
Screening digital rectal examination and prostate cancer mortality: a case-control study.
J Med Screen. 1998;5(2):99-103. doi: 10.1136/jms.5.2.99.
7
Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.使用前列腺特异性抗原水平<2.5ng/mL 的男性进行数字直肠检查(DRE)早期检测高级别前列腺癌与死亡风险。
BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.
8
Is routine digital rectal examination required for the followup of prostate cancer?前列腺癌随访需要常规直肠指检吗?
J Urol. 2007 Jul;178(1):115-9. doi: 10.1016/j.juro.2007.03.010. Epub 2007 May 11.
9
20-year outcomes following conservative management of clinically localized prostate cancer.临床局限性前列腺癌保守治疗后的20年随访结果
JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095.
10
Screening for prostate cancer: updated experience from the Tyrol study.前列腺癌筛查:蒂罗尔研究的最新经验
Can J Urol. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.

引用本文的文献

1
Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.数字直肠检查作为前列腺特异性抗原检测的辅助手段在临床上显著前列腺癌的检测中的应用。
J Urol. 2018 Apr;199(4):947-953. doi: 10.1016/j.juro.2017.10.021. Epub 2017 Oct 20.
2
Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic korean men.前列腺特异性抗原、直肠指检和经直肠超声检查:对有症状的韩国男性前列腺癌诊断三联征的荟萃分析
Yonsei Med J. 2005 Jun 30;46(3):414-24. doi: 10.3349/ymj.2005.46.3.414.
3
Toward a better understanding of the comparatively high prostate cancer incidence rates in Utah.
为了更好地理解犹他州相对较高的前列腺癌发病率。
BMC Cancer. 2003 Apr 29;3:14. doi: 10.1186/1471-2407-3-14.
4
Migration and prostate cancer: an international perspective.迁移与前列腺癌:国际视角
J Natl Med Assoc. 1998 Nov;90(11 Suppl):S720-3.
5
Prostate cancer screening (United States).
Cancer Causes Control. 1995 May;6(3):267-74. doi: 10.1007/BF00051798.
6
Prostate cancer, screening, and prostate-specific antigen: promise or peril?
J Gen Intern Med. 1994 Aug;9(8):468-74. doi: 10.1007/BF02599070.
7
Screening for ovarian, prostatic, and testicular cancers.卵巢癌、前列腺癌和睾丸癌筛查。
BMJ. 1994 Jul 30;309(6950):315-20. doi: 10.1136/bmj.309.6950.315.